title: The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-'BPH' study.
abstract: OBJECTIVE
  To evaluate the responsiveness of the ICSmale questionnaire to the outcome of treatments for lower urinary tract symptoms (LUTS).
  
  
  METHODS
  Consecutive men aged >45 years attending 23 urology centres in 12 countries, with symptoms suggestive of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH), were recruited to Phase I of the International Continence Society (ICS)-'BPH' study. In Phase II of the ICS-'BPH' study, 355 men in 15 centres in nine countries were followed up, having proceeded to treatment according to clinical practice. All men completed the ICS-'BPH' study questionnaire at baseline and follow-up, including the ICSmale which concerns LUTS and related problems.
  
  
  RESULTS
  Patients included in Phase II were similar to those in Phase I according to age and levels of baseline symptoms. Patients received a range of treatments: 32% TURP, 29% drug therapies, 20% watchful waiting, 9% minimally invasive therapies and 10% 'others' (including open prostatectomy). For patients who underwent TURP, most LUTS, including voiding and filling symptoms, were highly statistically significantly better at follow-up than at baseline (P<0.0001). For drug, minimally invasive and 'other' treatments, fewer LUTS were highly statistically significantly better. For those undergoing watchful waiting, no symptoms were significantly different between baseline and follow-up.
  
  
  CONCLUSIONS
  The ICSmale questionnaire, in addition to being psychometrically valid and reliable, is responsive to change in outcome.
authors.affiliation: Department of Social Medicine, University of Bristol, UK.
authors.forename: J L
authors.initials: JL
authors.lastname: Donovan
authors.forename: S T
authors.initials: ST
authors.lastname: Brookes
authors.forename: J J
authors.initials: JJ
authors.lastname: de la Rosette
authors.forename: T J
authors.initials: TJ
authors.lastname: Peters
authors.forename: D
authors.initials: D
authors.lastname: Porru
authors.forename: A
authors.initials: A
authors.lastname: Kondo
authors.forename: N
authors.initials: N
authors.lastname: Dabhoiwala
authors.forename: R
authors.initials: R
authors.lastname: Millard
authors.forename: R
authors.initials: R
authors.lastname: Bosch
authors.forename: J
authors.initials: J
authors.lastname: Nordling
authors.forename: A
authors.initials: A
authors.lastname: Matos Ferreira
authors.forename: K
authors.initials: K
authors.lastname: Höfner
authors.forename: H
authors.initials: H
authors.lastname: Mostafid
authors.forename: S
authors.initials: S
authors.lastname: Walter
authors.forename: I
authors.initials: I
authors.lastname: Nissenkorn
authors.forename: C
authors.initials: C
authors.lastname: Frimodt Moller
authors.forename: M
authors.initials: M
authors.lastname: Mendes Silva
authors.forename: C
authors.initials: C
authors.lastname: Chapple
authors.forename: P
authors.initials: P
authors.lastname: Abrams
mesh_terms: D000367:Age Factors; D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000592:standards; D011470:Prostatic Hyperplasia / Q000150:complications / Q000628:therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires / Q000592:standards*; D016896:Treatment Outcome; D001748:Urinary Bladder Neck Obstruction / Q000209:etiology / Q000628:therapy*